Price movement over the last 24 hours
Align Technology, Inc. vs Vanguard Growth Index Fund ETF — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while Vanguard Growth Index Fund ETF trades at $87.23. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | VUG | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $207.19 | $90.29 |
52-Week Low | $124.88 | $70.00 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
VUG trades at $87.4, up 0.48% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights its strong long-term growth focus, with 70% tech exposure and low expense ratio of 0.03%. The ETF executed a 1:6 stock split in April 2026 and has a dividend scheduled for June 2026.
Outlook remains positive due to tech-driven growth and cost efficiency, but risks include high tech concentration and market volatility. Analyst sentiment is favorable for long-term holdings, though short-term indicators suggest caution near resistance levels.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →